Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2015', provides an overview of the Venous Leg Ulcers (Crural ulcer)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Venous Leg Ulcers (Crural ulcer) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Venous Leg Ulcers (Crural ulcer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Venous Leg Ulcers (Crural ulcer) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Venous Leg Ulcers (Crural ulcer) Overview 7
Therapeutics Development 8
Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Overview 8
Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis 9
Venous Leg Ulcers (Crural ulcer) - Therapeutics under Development by Companies 10
Venous Leg Ulcers (Crural ulcer) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Venous Leg Ulcers (Crural ulcer) - Products under Development by Companies 14
Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development 15
Adocia 15
CardioVascular BioTherapeutics, Inc. 16
CoDa Therapeutics, Inc. 17
CytoTools AG 18
FirstString Research, Inc. 19
Intralytix, Inc. 20
MacroCure Ltd. 21
Pergamum AB 22
RegeneRx Biopharmaceuticals, Inc. 23
Smith & Nephew Plc 24
Stratatech Corporation 25
Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
Cathelicidin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CL-05 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CODA-001 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CureXcell - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CVBT-141B - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Granexin - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
HP-802247 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
LL-37 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
RGN-137 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
WPP-201 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Venous Leg Ulcers (Crural ulcer) - Recent Pipeline Updates 52
Venous Leg Ulcers (Crural ulcer) - Dormant Projects 59
Venous Leg Ulcers (Crural ulcer) - Discontinued Products 60
Venous Leg Ulcers (Crural ulcer) - Product Development Milestones 61
Featured News & Press Releases 61
Oct 13, 2014: Smith & Nephew announces top-line results of HP802-247 Phase 3 study 61
May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication 61
Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers 62
Sep 11, 2012: Healthpoint Biotherapeutics Initiates Phase III Study Of Investigational Cell-Based Therapy For Venous Leg Ulcers 62
Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet 63
Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers 64
Aug 04, 2011: Healthpoint Biotherapeutics Announces Positive Results From Phase IIb Trial Of HP802-247 In Venous Leg Ulcers 65
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results 66
Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69

List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2015 8
Number of Products under Development for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Venous Leg Ulcers (Crural ulcer) - Pipeline by Adocia, H1 2015 15
Venous Leg Ulcers (Crural ulcer) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2015 16
Venous Leg Ulcers (Crural ulcer) - Pipeline by CoDa Therapeutics, Inc., H1 2015 17
Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H1 2015 18
Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research, Inc., H1 2015 19
Venous Leg Ulcers (Crural ulcer) - Pipeline by Intralytix, Inc., H1 2015 20
Venous Leg Ulcers (Crural ulcer) - Pipeline by MacroCure Ltd., H1 2015 21
Venous Leg Ulcers (Crural ulcer) - Pipeline by Pergamum AB, H1 2015 22
Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 23
Venous Leg Ulcers (Crural ulcer) - Pipeline by Smith & Nephew Plc, H1 2015 24
Venous Leg Ulcers (Crural ulcer) - Pipeline by Stratatech Corporation, H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Venous Leg Ulcers (Crural ulcer) Therapeutics - Recent Pipeline Updates, H1 2015 52
Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H1 2015 59
Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H1 2015 60